Risk of MACE With Tofacitinib vs TNF Inhibitors in Patients With Rheumatoid Arthritis With or Without a History of Atherosclerotic Cardiovascular Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Ann. Rheum. Dis 2022 Sep 22;[EPub Ahead of Print], C Charles-Schoeman, MH Buch, M Dougados, DL Bhatt, JT Giles, SR Ytterberg, GG Koch, I Vranic, J Wu, C Wang, K Kwok, S Menon, JL Rivas, A Yndestad, CA Connell, Z SzekaneczFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.